PMID- 31464934
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 35
DP  - 2019 Aug
TI  - Efficacy and safety of berberine in the treatment of type 2 diabetes with insulin 
      resistance: Protocol for a systematic review.
PG  - e16947
LID - 10.1097/MD.0000000000016947 [doi]
LID - e16947
AB  - BACKGROUND: The incidence of diabetes mellitus (DM) is increasing year by year, 
      and various complications can endanger the lives of patients. Type 2 diabetes 
      mellitus (T2DM) accounts for more than 90% of DM, most of which is associated 
      with insulin resistance (IR), and IR has been shown to be closely related to the 
      onset of T2DM and the presence of DM complications. Berberine (BBR) has been 
      shown to improve T2DM with IR in a number of ways. In this study, we aim to 
      evaluate the efficacy and safety of BBR in the treatment of T2DM with IR to 
      provide the newest evidence for clinical use. METHODS AND ANALYSIS: Literature 
      research will be divided into 2 parts: electronic search and manual search. We 
      will search PubMed, EMBASE, The Cochrane Library, the China National Knowledge 
      Infrastructure, China Biology Medicine disc, the China Science and Technology 
      Journal database, and the Wanfang database online. We will select the eligible 
      studies published up to June 30, 2019. Dissertations, conference papers, ongoing 
      trials, internal reports, etc., are searched by manual search methods. We use 
      Homeostatic Model Assessment for IR (HOMA-IR) as the primary outcome of T2DM with 
      IR, and we will also focus on the patient's blood glucose levels and all adverse 
      reactions that occur during medication.Two reviewers will read the articles, 
      extract the data information, and assess the risk of bias independently. Data 
      analysis will use the software such as RevMan 5.3.5, ENDNOTE X7, and STATA 13.0. 
      RESULTS: This study will provide a high-quality synthesis of current evidence of 
      BBR for T2DM with IR from several aspects including HOMA-IR, blood glucose 
      levels, and adverse events. CONCLUSION: This systematic review will provide 
      evidence to assess the efficacy and safety of BBR in the treatment of T2DM with 
      IR. ETHICS AND DISSEMINATION: Because all of the data used in this systematic 
      review has been published, ethical approval is not required. TRIAL REGISTRATION 
      NUMBER: PROSPERO CRD42019123225.
FAU - Wang, Yinshan
AU  - Wang Y
AD  - Department of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, 
      Kaifeng.
FAU - Yan, Aihua
AU  - Yan A
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Li, Shanshan
AU  - Li S
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Liu, Bei
AU  - Liu B
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Li, Huimin
AU  - Li H
AD  - Henan University of Chinese Medicine, Zhengzhou, China.
FAU - Yan, Yong
AU  - Yan Y
AD  - Department of Endocrinology, Kaifeng Hospital of Traditional Chinese Medicine, 
      Kaifeng.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0I8Y3P32UF (Berberine)
SB  - IM
MH  - Berberine/administration & dosage/adverse effects/*therapeutic use
MH  - Blood Glucose
MH  - China
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Insulin Resistance/*physiology
MH  - Randomized Controlled Trials as Topic
MH  - *Research Design
PMC - PMC6736273
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2019/08/30 06:00
MHDA- 2019/09/17 06:00
PMCR- 2019/08/30
CRDT- 2019/08/30 06:00
PHST- 2019/08/30 06:00 [entrez]
PHST- 2019/08/30 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
PHST- 2019/08/30 00:00 [pmc-release]
AID - 00005792-201908300-00046 [pii]
AID - MD-D-19-05747 [pii]
AID - 10.1097/MD.0000000000016947 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Aug;98(35):e16947. doi: 10.1097/MD.0000000000016947.